Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
CDK inhibitors block cyclin-dependent kinases (CDKs), the serine/threonine kinases that drive the cell cycle. Each CDK becomes active only when bound to a cyclin partner, and successive cyclin-CDK complexes order DNA replication and mitosis. CDK4 and CDK6 pair with D-type cyclins to control progression through G1, while CDK1 governs entry into mitosis. Palbociclib and abemaciclib are selective CDK4/6 inhibitors used to study G1 arrest and retinoblastoma protein phosphorylation. Dinaciclib and seliciclib act on several family members, including CDK2, CDK5 and CDK9, which also links them to transcription research. Ro 3306 inhibits CDK1 and is used to hold cells reversibly at the G2/M boundary for synchronization experiments.
CDK7-IN-1 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7), demonstrating an IC50 of less than 100 nM. This compound effectively modulates CDK7 activity, disrupting cell cycle progression and transcription regulation. CDK7-IN-1 is suitable for research applications related to cancer biology and therapeutic development targeting aberrant cell proliferation.
(S)-LY3177833 hydrate is a selective inhibitor of CDC7 kinase, playing a crucial role in DNA replication and cell cycle regulation. This compound exhibits significant in vitro anticancer activity across various cancer cell lines, making it a valuable tool for studying cancer biology. Its application in research extends to investigations of cell proliferation and therapeutic strategies targeting DNA replication mechanisms.
IV-361 is a selective cyclin-dependent kinase 7 (CDK7) inhibitor with a Ki value of less than 50 nM. This compound exhibits significant anti-cancer activity, making it a valuable tool for researchers investigating cancer cell proliferation and survival pathways. IV-361's specificity for CDK7 allows for in-depth studies of its role in transcription regulation and potential therapeutic applications in cancer treatment.
LY3177833 monhydrate is a potent CDC7 inhibitor, demonstrating an IC50 of 3.3 nM, alongside its activity against pMCM2 with an IC50 of 290 nM. This compound is recognized for its ability to induce cellular senescence, making it a valuable tool in cancer research and studies related to cell cycle regulation. Its oral bioavailability enhances its applicability in in vivo studies, facilitating the exploration of CDC7-targeted therapeutic strategies.
Cdc7-IN-5 is a potent inhibitor of Cdc7 kinase, a crucial serine-threonine protein kinase that plays a key role in the initiation of DNA replication during the cell cycle. This compound serves as a valuable tool for investigating the regulation of DNA replication and cell cycle progression. Its application extends to studying cancer biology and potential therapeutic interventions targeting DNA replication mechanisms.
Cimpuciclib tosylate is a potent selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 0.49 nM. Its strong inhibitory activity is associated with anti-tumor effects and promotes cell cycle arrest in cancer research. This compound is valuable for studies focused on tumor proliferation and therapeutic strategies targeting CDK4 in various cancer types.
CDK4/6-IN-18 is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It demonstrates the ability to effectively inhibit ionizing radiation-induced DNA damage in cellular models. This compound is a valuable tool for research focused on cancer biology and therapies that target the cell cycle and DNA damage response pathways.
CDK6-IN-1 is a selective inhibitor of cyclin-dependent kinase 6 (CDK6), functioning primarily by impeding cell growth and promoting G1-phase cell cycle arrest. This compound has significant implications in cancer research, particularly in studies targeting cell proliferation and tumorigenesis. Its efficacy in modulating cell cycle progression makes it a valuable tool for investigating mechanisms of cancer therapy and the role of CDK6 in malignancies.
JNJ-3738 is a selective inhibitor of cyclin-dependent kinase 7 (CDK7) with a Ki value of 21.75 nM. This compound demonstrates potent inhibitory activity in CDK7 wild-type expressing A549 cells, exhibiting a pIC50 of 7.37. JNJ-3738 is primarily utilized in research applications focused on cell cycle regulation, transcriptional control, and cancer biology.
PPA-037 is a potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12) with oral bioavailability. By inducing the degradation of cyclin K, PPA-037 enhances antiproliferative effects on various tumor cells. This compound holds significant potential for cancer research applications focused on targeting CDK12-related pathways.
Out of stock
All 3 sizes![[Ala92]-p16 (84-103)](https://www.adooq.com/media/catalog/product/cache/16359f9c8ddfa823fcb5503b1e11b7ae/a/5/a54259-ala92-p16-84-103.gif)
[Ala92]-p16 (84-103) is a peptide derived from the p16CDKN2/INK4a tumor suppressor protein that targets CDK4-Cyclin D1 kinase. This peptide effectively binds to CDK4 and CDK6, demonstrating an inhibitory effect on CDK4-cyclin D1 activity with an IC50 of 1.5 μM. Its mechanism of action leads to the blockade of cell cycle progression through the G1 phase, making it a valuable reagent for cancer research and studies focusing on cell cycle regulation.
SNX7 is a selective inhibitor of the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. This compound plays a crucial role in studying cellular senescence and various CDKI-related diseases. By targeting the CDKI pathway, SNX7 serves as a valuable tool in cancer research and other conditions where cell cycle regulation is disrupted.
CDK12/13-IN-3 is a selective inhibitor of cyclin-dependent kinases 12 and 13, demonstrating IC50 values of 107.4 nM and 79.4 nM, respectively. This compound effectively inhibits the phosphorylation of Ser2 on the C-terminal domain of RNA polymerase II, leading to DNA damage and downregulation of DNA damage response gene expression. CDK12/13-IN-3 exhibits notable antiproliferative activity against a variety of cancer cell lines and shows significant antitumor effects in mouse models, supported by favorable pharmacokinetic properties, including an oral bioavailability of 53.6%.
XPW1 is a potent and selective inhibitor of CDK9, a key regulator in transcriptional control linked to cancer progression. This compound exhibits significant anti-tumor activity against clear cell renal cell carcinoma (ccRCC) and demonstrates favorable toxicity profiles. Its unique mechanism of action makes it a valuable tool for research into CDK9's role in cancer biology and therapeutic interventions.
CDK7-IN-28 is a potent inhibitor of cyclin-dependent kinase 7 (CDK7) with an IC50 value of less than 5 nM. This compound effectively impedes cell proliferation in the MDA-MB-468 cell line by interfering with cell cycle progression and inhibiting DNA replication. Its activity makes it a valuable tool for research into cell cycle regulation and cancer therapeutics.
Out of stock
All 3 sizes
CDK2-IN-37 is a selective cyclin-dependent kinase 2 (CDK2) inhibitor that demonstrates significant anti-cancer properties. By effectively inhibiting CDK2 activity, it disrupts cell cycle progression and promotes apoptosis in cancer cells. This compound is a valuable tool for researchers investigating the role of CDK2 in cancer biology and therapeutic development.
(E/Z)-THZ1 dihydrochloride is a potent and selective inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 3.2 nM. This compound exhibits significant antiproliferative activity, making it a valuable tool for research in cancer biology and cell cycle regulation. Its ability to inhibit CDK7 can be utilized in studies aimed at understanding transcriptional regulation and therapeutic strategies for various malignancies.
(S)-(-)-O-Demethylbuchenavianine is a flavonoidal alkaloid that functions as a potent inhibitor of cyclin-dependent kinases (CDKs), specifically targeting CDK1 and CDK5 with IC50 values of 0.03 and 0.05 μM, respectively. This compound is valuable for research applications focused on cell cycle regulation and the investigation of CDK-related signaling pathways. Its inhibitory activity makes it an important tool for studying the role of CDKs in various biological processes and diseases.
CDK4-IN-1 is a selective inhibitor of Cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 of 10 nM. This compound demonstrates significant specificity, being 1500-fold and 500-fold less potent against CDK1/Cyclin B and CDK2/Cyclin A, respectively, with IC50 values greater than 15 µM and 5 µM. CDK4-IN-1 is primarily utilized in research focused on cell cycle regulation and anti-cancer therapies, particularly in the context of cancers characterized by aberrant CDK4 activity.
Synonyms: PD-0332991 dihydrochloride
Palbociclib dihydrochloride is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) with IC50 values of 11 nM and 16 nM, respectively. This compound exhibits significant anti-proliferative effects and induces cell cycle arrest in various cancer cell lines. It is particularly relevant for research applications in hormone receptor-positive and HER2-negative breast cancer, as well as hepatocellular carcinoma, providing insights into tumor growth regulation and potential therapeutic strategies.
Out of stock
All 3 sizes
Synonyms: PD 0332991 orotate
Palbociclib orotate is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), demonstrating IC50 values of 11 nM and 16 nM, respectively. This compound exhibits significant anti-proliferative activity, effectively inducing cell cycle arrest in cancer cells. Palbociclib orotate is primarily utilized in research focused on HR-positive and HER2-negative breast cancer as well as hepatocellular carcinoma, making it a valuable tool for understanding therapeutic strategies in these malignancies.
Out of stock
All 3 sizes
CDK1-IN-5 is a selective inhibitor of cyclin-dependent kinase 1 (CDK1), demonstrating IC50 values of 42.19 nM for CDK1, 188.71 nM for CDK2, and 354.15 nM for CDK5. By targeting CDK1, this compound effectively disrupts cell cycle progression and inhibits the growth of cancer cells. CDK1-IN-5 is valuable for research applications focused on cancer biology and therapeutic strategies against tumor proliferation.
Out of stock
All 3 sizes
Cimpuciclib is a selective inhibitor of cyclin-dependent kinase 4 (CDK4), exhibiting an IC50 value of 0.49 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for cancer research. Its inhibition of CDK4 disrupts cell cycle progression, thus providing insights into therapeutic strategies for tumors driven by CDK4 dysregulation.
CDK1-IN-3 is a selective inhibitor of Cyclin-dependent kinase 1 (CDK1), exhibiting IC50 values of 36.8 nM, 305.17 nM, and 369.37 nM for CDK1, CDK2, and CDK5, respectively. This compound effectively disrupts the cell cycle, leading to inhibition of cancer cell proliferation. CDK1-IN-3 is valuable for research applications targeting cancer biology and therapeutic development in oncology.
Out of stock
All 3 sizes
Synonyms: RGT-419B
GDC-4198 is an orally active inhibitor of cyclin-dependent kinases 4 and 2 (CDK4/2), exhibiting selective activity against kinases such as CDK6, CDK9, and GSK3β. By inhibiting cyclin-CDK complexes, GDC-4198 effectively blocks the phosphorylation of retinoblastoma protein (pRb), thus halting the cell cycle progression from the G1 to S phase. This compound is a valuable tool for investigating various cancers, particularly breast cancer (especially hormone receptor-positive, HER2-negative), lung cancer, and colorectal cancer.
